Okamoto Hiroaki, Li Jie, Gläsker Sven, Vortmeyer Alexander O, Jaffe Howard, Robison R Aaron, Bogler Oliver, Mikkelsen Tom, Lubensky Irina A, Oldfield Edward H, Zhuang Zhengping
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland 20892-1414, USA.
Cancer Biol Ther. 2007 Mar;6(3):391-6. doi: 10.4161/cbt.6.3.3731. Epub 2007 Mar 20.
Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH.
In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting.
We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia.
These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.
化疗耐药是胶质肿瘤中普遍存在的治疗挑战。化疗耐药的分子基础尚不清楚,这阻碍了胶质瘤治疗的进展,使胶质瘤成为最致命的肿瘤之一。少突胶质细胞瘤提供了一个研究化疗耐药分子基础的独特模型,因为存在两种不同的基因亚型,其化疗敏感性有显著差异。尽管形态学相似度高,但染色体1短臂等位基因缺失(1pLOH)的肿瘤比无1pLOH的肿瘤对化疗更敏感。
为了鉴定可能与胶质瘤化疗敏感性相关的候选蛋白,我们使用比较蛋白质组学分析方法,比较了4例有1pLOH和5例无1pLOH的少突胶质细胞瘤的蛋白质组。蛋白质组分析通过二维蛋白质凝胶电泳及随后的计算机凝胶分析来检测蛋白质表达的差异模式。使用液相色谱/质谱法鉴定差异表达的蛋白质。通过蛋白质印迹法确认所选蛋白质的差异表达。
我们鉴定出7种在无1pLOH的少突胶质细胞瘤中过表达的候选蛋白。其中两种蛋白(乙二醛酶I和Rho GDP解离抑制剂)先前已被证明可增强其他肿瘤的化疗耐药性。反过来,我们在有1pLOH的肿瘤中鉴定出12种过表达的蛋白,这些蛋白先前已被报道可诱导其他形式人类肿瘤的化疗敏感性。
这些鉴定出的蛋白是药物治疗的潜在靶点,也可能作为区分化疗耐药和化疗敏感少突胶质细胞瘤的生物标志物。